Search research articles
Contact Us
Filters
Showing results (571-580 of 1,206) with videos related to
Page
of 121
Sort By:
Health Affairs (Project Hope)
|
January 6, 2010
Cancer therapy costs influence treatment: a national survey of oncologists
Peter J Neumann, Jennifer A Palmer, Eric Nadler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]
Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
Health Affairs (Project Hope)
|
November 19, 2020
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic
Peter J Neumann, Joshua T Cohen, David D Kim, et al.
BMJ Global Health
|
March 6, 2020
Are low and middle-income countries prioritising high-value healthcare interventions?
Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Pharmacoeconomics - Open
|
July 23, 2022
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates
Rachel Milstein Breslau, Joshua T Cohen, Daniel A Ollendorf, et al.
American Journal of Preventive Medicine
|
October 17, 2015
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review
Aaron N Winn, Donatus U Ekwueme, Gery P Guy, et al.
The American Journal of Managed Care
|
September 8, 2000
Barriers to using cost-effectiveness analysis in managed care decision making
L A Prosser, J P Koplan, P J Neumann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 17, 2013
Willingness to pay for diagnostic technologies: a review of the contingent valuation literature
Pei-Jung Lin, Michael J Cangelosi, David W Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 15, 2018
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies
Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Do Specialty Drugs Offer Greater Value for Money Than Traditional Drugs?
J D Chambers, T Thorat, M Chenoweth, et al.
Page
of 121
Search research articles
Search
Showing results (571-580 of 1,206) with videos related to
Sort By:
Page
of 121
Health Affairs (Project Hope)
|
January 6, 2010
Cancer therapy costs influence treatment: a national survey of oncologists
Peter J Neumann, Jennifer A Palmer, Eric Nadler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]
Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
Health Affairs (Project Hope)
|
November 19, 2020
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic
Peter J Neumann, Joshua T Cohen, David D Kim, et al.
BMJ Global Health
|
March 6, 2020
Are low and middle-income countries prioritising high-value healthcare interventions?
Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Pharmacoeconomics - Open
|
July 23, 2022
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates
Rachel Milstein Breslau, Joshua T Cohen, Daniel A Ollendorf, et al.
American Journal of Preventive Medicine
|
October 17, 2015
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review
Aaron N Winn, Donatus U Ekwueme, Gery P Guy, et al.
The American Journal of Managed Care
|
September 8, 2000
Barriers to using cost-effectiveness analysis in managed care decision making
L A Prosser, J P Koplan, P J Neumann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 17, 2013
Willingness to pay for diagnostic technologies: a review of the contingent valuation literature
Pei-Jung Lin, Michael J Cangelosi, David W Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 15, 2018
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies
Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Do Specialty Drugs Offer Greater Value for Money Than Traditional Drugs?
J D Chambers, T Thorat, M Chenoweth, et al.
Page
of 121